{"id":89480,"date":"2024-10-14T10:07:24","date_gmt":"2024-10-14T08:07:24","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=89480"},"modified":"2024-10-14T10:11:19","modified_gmt":"2024-10-14T08:11:19","slug":"inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/","title":{"rendered":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d’euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH"},"content":{"rendered":"

Inventiva (Euronext Paris et Nasdaq: IVA) (\u00ab Inventiva <\/b>\u00bb ou la \u00ab Soci\u00e9t\u00e9 <\/b>\u00bb), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement clinique de petites mol\u00e9cules administr\u00e9es par voie orale pour le traitement de la st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique (\u00ab MASH <\/b>\u00bb) et d\u2019autres maladies avec un besoin m\u00e9dical non satisfait, annonce aujourd’hui un financement imm\u00e9diat de 94,1 millions d\u2019euros et jusqu’\u00e0 348 millions d’euros (l\u2019 \u00ab Op\u00e9ration <\/b>\u00bb), sous r\u00e9serve de la satisfaction de conditions sp\u00e9cifiques, pour financer l\u2019ach\u00e8vement de l\u2019\u00e9tude de Phase 3, NATiV3, dans la MASH et la pr\u00e9paration pour le d\u00e9p\u00f4t potentiel d\u2019une demande d\u2019autorisation sur mise sur le march\u00e9 et la commercialisation de lanifibranor.\u00a0<\/span><\/p>\n

Le financement a \u00e9t\u00e9 men\u00e9 par New Enterprise Associates, BVF Partners LP and Samsara BioCapital, avec la participation d\u2019existants et de nouveaux investisseurs dont Andera Partners, Deep Track Capital, Eventide Asset Management, Great Point Partners, Invus, Perceptive Advisors, LLC, Schonfeld Strategic Advisors and Sofinnova Crossover I SLP.\u00a0<\/span><\/p>\n

Dans le cadre de l\u2019Op\u00e9ration, et sous r\u00e9serve de la ratification par les actionnaires lors de l\u2019assembl\u00e9e g\u00e9n\u00e9rale devant \u00eatre r\u00e9unie au plus tard le 16 d\u00e9cembre 2024, la Soci\u00e9t\u00e9 a nomm\u00e9 Mark Pruzanski, MD, en tant que Pr\u00e9sident du conseil d\u2019administration et Srinivas Akkaraju, MD, PhD, en tant qu\u2019administrateur. Jusqu\u2019\u00e0 quatre administrateurs suppl\u00e9mentaires pourront \u00eatre nomm\u00e9s par chacun des quatre investisseurs principaux, dont deux seront administrateurs qualifi\u00e9s d\u2019ind\u00e9pendants et remplaceront les administrateurs existants (\u00e0 l’exclusion de Fr\u00e9d\u00e9ric Cren, Mark Pruzanski et Srinivas Akkaraju).\u00a0<\/span><\/p>\n

Dr. Mark Pruzanski a d\u00e9clar\u00e9 : <\/b>\u00ab J’ai longtemps cru au potentiel th\u00e9rapeutique du lanifibranor dans la MASH et je suis honor\u00e9 par la perspective de rejoindre Inventiva en tant que pr\u00e9sident. Sur la base des r\u00e9sultats de l’\u00e9tude de Phase 2b NATIVE pr\u00e9c\u00e9demment publi\u00e9s, lanifibranor pr\u00e9sente un profil qui le positionne comme un m\u00e9dicament oral potentiellement \u00ab best-in class \u00bb : ses effets sur la sensibilit\u00e9 \u00e0 l’insuline et anti-fibrotique direct font de lanifibranor une th\u00e9rapie id\u00e9ale pour la majorit\u00e9 de la population de patients diab\u00e9tiques de type 2 souffrant de fibrose avanc\u00e9e due \u00e0 la MASH, patients les plus \u00e0 risque de progression vers une insuffisance h\u00e9patique. Avec un soutien financier annonc\u00e9 aujourd\u2019hui, allant jusqu\u2019\u00e0 $410 millions, et j’ai h\u00e2te de travailler avec Fr\u00e9d\u00e9ric et le reste du Conseil et aider la Soci\u00e9t\u00e9 \u00e0 maximiser sa capacit\u00e9 \u00e0 r\u00e9aliser la promesse de lanifibranor. \u00bb\u00a0<\/span><\/i><\/p>\n

J.P. Morgan, TD Cowen, Guggenheim Securities, and LifeSci Capital agissent en qualit\u00e9 d\u2019agents pour le placement, et Namsem Capital agit en qualit\u00e9 de conseil en march\u00e9s de capitaux de la Soci\u00e9t\u00e9.\u00a0<\/span><\/p>\n

Fr\u00e9d\u00e9ric Cren, directeur g\u00e9n\u00e9ral, a d\u00e9clar\u00e9 : <\/b>\u00ab Je suis tr\u00e8s heureux d’annoncer ce financement important \u00e0 un moment crucial pour la Soci\u00e9t\u00e9. Cela refl\u00e8te la confiance des investisseurs participants et de notre partenaire CTTQ dans la valeur du lanifibranor en tant que th\u00e9rapie novatrice pour les patients souffrant de MASH. Le produit de ce financement soutiendra le programme MASH et le d\u00e9p\u00f4t ult\u00e9rieur pour une possible autorisation de mise sur le march\u00e9, ainsi que la pr\u00e9paration \u00e0 une commercialisation potentielle du lanifibranor. Je tiens \u00e9galement \u00e0 souligner l\u2019importance de l’expertise approfondie dans le domaine du MASH que Mark apporte \u00e0 Inventiva et j’ai h\u00e2te de travailler avec lui afin de garantir les meilleures chances d’amener lanifibranor aux patients. \u00bb\u00a0<\/span><\/i><\/p>\n

Dr. Nezam (\u00ab Nid \u00bb) Afdhal, MD, Chef de gastroent\u00e9rologie, Beth Israel Deaconess Medical Center et Professeur de m\u00e9decine, Harvard Medical School, a d\u00e9clar\u00e9 <\/b>: \u00ab Les chercheurs et les cliniciens restent enthousiastes dans le potentiel du lanifibranor dans la MASH en raison de son effet sur l’am\u00e9lioration de la fibrose et de la r\u00e9solution de la MASH. L\u2019activation des PPARs par le lanifibranor a \u00e9galement d\u00e9montr\u00e9 une am\u00e9lioration du profil m\u00e9tabolique et du risque cardiovasculaire chez nos patients atteints de MASH. Ce double b\u00e9n\u00e9fice pourrait faire du lanifibranor une solution id\u00e9ale pour les patients souffrant de MASH, de fibrose significative et de diab\u00e8te. <\/i>\u00bb\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Inventiva (Euronext Paris et Nasdaq: IVA) (\u00ab Inventiva \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement clinique de petites mol\u00e9cules administr\u00e9es par voie orale pour le traitement de la st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique (\u00ab MASH \u00bb) et d\u2019autres maladies avec un besoin m\u00e9dical non satisfait, annonce aujourd’hui un financement…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[78],"class_list":["post-89480","post","type-post","status-publish","format-standard","hentry","category-biodiscovery"],"acf":[],"yoast_head":"\nInventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Inventiva (Euronext Paris et Nasdaq: IVA) (\u00ab Inventiva \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement clinique de petites mol\u00e9cules administr\u00e9es par voie orale pour le traitement de la st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique (\u00ab MASH \u00bb) et d\u2019autres maladies avec un besoin m\u00e9dical non satisfait, annonce aujourd’hui un financement...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-14T08:07:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T08:11:19+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d’euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH\",\"datePublished\":\"2024-10-14T08:07:24+00:00\",\"dateModified\":\"2024-10-14T08:11:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\"},\"wordCount\":733,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\",\"name\":\"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2024-10-14T08:07:24+00:00\",\"dateModified\":\"2024-10-14T08:11:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d’euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/","og_locale":"fr_FR","og_type":"article","og_title":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS","og_description":"Inventiva (Euronext Paris et Nasdaq: IVA) (\u00ab Inventiva \u00bb ou la \u00ab Soci\u00e9t\u00e9 \u00bb), soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement clinique de petites mol\u00e9cules administr\u00e9es par voie orale pour le traitement de la st\u00e9atoh\u00e9patite associ\u00e9e \u00e0 un dysfonctionnement m\u00e9tabolique (\u00ab MASH \u00bb) et d\u2019autres maladies avec un besoin m\u00e9dical non satisfait, annonce aujourd’hui un financement...","og_url":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2024-10-14T08:07:24+00:00","article_modified_time":"2024-10-14T08:11:19+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d’euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH","datePublished":"2024-10-14T08:07:24+00:00","dateModified":"2024-10-14T08:11:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/"},"wordCount":733,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/","url":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/","name":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d'euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2024-10-14T08:07:24+00:00","dateModified":"2024-10-14T08:11:19+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/inventiva-annonce-un-financement-allant-jusqua-348-millions-deuros-afin-davancer-letude-nativ3-de-phase-3-dans-la-mash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Inventiva annonce un financement allant jusqu\u2019\u00e0 348 millions d’euros afin d\u2019avancer l\u2019\u00e9tude NATiV3 de Phase 3 dans la MASH"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=89480"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89480\/revisions"}],"predecessor-version":[{"id":89483,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/89480\/revisions\/89483"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=89480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=89480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}